• HOME
  • Pipeline
  • Clinical Focus
  • Technology
  • Team
  • News
  • About
  • HOME
  • Pipeline
  • Clinical Focus
  • Technology
  • Team
  • News
  • About
  • canstockphoto6244971

    Febrile neutropenia is a common,
    life-threatening
    complication of chemotherapy

  • canstockphoto62820667

    Gut barrier Injury and Neutrophil
    depletion puts patients at risk for
    bacteremia and sepsis

  • canstockphoto7427952

    AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
    BACTERAEMIA BY STRENGTHENING
    INNATE GUT BARRIER DEFENSES

  • N1WT6iuIb

    eliminating the need for prophylactiC antibiotics

  • V1fz3suL-

    reducing risk of serious adverse events,
    antimicrobial resistance and
    microbiome dysbiosis

  • HOME
  • News
  • Grant from Cancer Society

Grant from Cancer Society

Akthelia founder awarded

June 6, 2022

Akthelia's founder Guðmundur Hrafn Guðmundsson was recently awarded a grant from the Icelandic Cancer Society to fund research into prophylactic therapies for febrile neutropenia..

More information on the Society's web site.

AKTHELIA

  • Grandagarði 16, 101 Reykjavik
  • akthelia@akthelia.is
  • 610502-6440
  • Twitter
© 2023 AKTHELIA